View in EDS

Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?

Saved in:
Bibliographic Details
Title: Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?
Authors: Choby JE; Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA., Ozturk T; Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA., Satola SW; Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA; Georgia Emerging Infections Programme, Atlanta, GA, USA., Jacob JT; Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA; Georgia Emerging Infections Programme, Atlanta, GA, USA., Weiss DS; Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: david.weiss@emory.edu.
Source: The Lancet. Microbe [Lancet Microbe] 2021 Dec; Vol. 2 (12), pp. e648-e649. Date of Electronic Publication: 2021 Oct 28.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101769019 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-5247 (Electronic) Linking ISSN: 26665247 NLM ISO Abbreviation: Lancet Microbe Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-5247
DOI:10.1016/S2666-5247(21)00271-8